Glycosylated ligand/receptor specificity exchangers specific for bacterial adhesion receptors
The present invention generally relates to compositions and methods for preventing and treating human diseases including, but not limited to, pathogens such as bacteria, yeast, parasites, fungus, viruses, and cancer. More specifically, embodiments described herein concern the manufacture and use of ligand/receptor specificity exchangers, which redirect existing antibodies in a subject to receptors present on pathogens.
1. A glycosylated ligand/receptor specificity exchanger comprising:
at least one specificity domain comprising a ligand for a bacterial adhesion receptor; and
at least one antigenic domain joined to said specificity domain.
2. The ligand/receptor specificity exchanger of claim 1 , wherein said ligand is a fragment of fibrinogen.
3. The ligand/receptor specificity exchanger of claim 1 , wherein said bacterial adhesion receptor is a Staphylococcal adhesion receptor.
4. The ligand/receptor specificity exchanger of claim 3 , wherein said Staphylococcal adhesion receptor is selected from the group consisting of ClfA, ClfB, Efb, and Fbe.
5. The ligand/receptor specificity exchanger of claim 4 , wherein said wherein said Staphylococcal adhesion receptor is ClfA or ClfB.
6. The ligand/receptor specificity exchanger of claim 4 , wherein said wherein said Staphylococcal adhesion receptor is ClfA.
7. The ligand/receptor specificity exchanger of claim 1 , wherein said ligand is between 3 and 20 amino acids in length.
8. A ligand/receptor specificity exchanger comprising a plurality of saccharides and at least one specificity domain joined to at least one antigenic domain, wherein said specificity domain comprises a ligand for a bacterial adhesion receptor.
9. The ligand/receptor specificity exchanger of claim 8 , wherein said ligand is a fragment of fibrinogen.
10. The ligand/receptor specificity exchanger of claim 8 , wherein said bacterial adhesion receptor is a Staphylococcal adhesion receptor.
11. The ligand/receptor specificity exchanger of claim 10 , wherein said Staphylococcal adhesion receptor is selected from the group consisting of ClfA, ClfB, Efb, and Fbe.
12. The ligand/receptor specificity exchanger of claim 11 , wherein said wherein said Staphylococcal adhesion receptor is ClfA or ClfB.
13. The ligand/receptor specificity exchanger of claim 11 , wherein said wherein said Staphylococcal adhesion receptor is ClfA.
14. The ligand/receptor specificity exchanger of claim 8 , wherein said ligand is between 3 and 20 amino acids in length.
15. A ligand/receptor specificity exchanger comprising at least one specificity domain joined to at least one antigenic domain, wherein said specificity domain comprises a ligand for a bacterial adhesion receptor and said ligand/receptor specificity exchanger is joined to a saccharide support.
16. The ligand/receptor specificity exchanger of claim 15 , wherein said ligand is a fragment of fibrinogen.
17. The ligand/receptor specificity exchanger of claim 15 , wherein said bacterial adhesion receptor is a Staphylococcal adhesion receptor.
18. The ligand/receptor specificity exchanger of claim 17 , wherein said Staphylococcal adhesion receptor is selected from the group consisting of ClfA, ClfB, Efb, and Fbe.
19. The ligand/receptor specificity exchanger of claim 18 , wherein said wherein said Staphylococcal adhesion receptor is ClfA or ClfB.
20. The ligand/receptor specificity exchanger of claim 18 , wherein said wherein said Staphylococcal adhesion receptor is ClfA.
21. The ligand/receptor specificity exchanger of claim 15 , wherein said ligand is between 3 and 20 amino acids in length.